EHA 2023 | Incorporating immunotherapy into the first-line treatment of ALL
Josep-Maria Ribera
• 9 Jun 2023
Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the need to reduce toxicity and increase the efficacy of first-line intensive chemotherapy in acute lymphoblastic leukemia (ALL). He comments that the addition of immunotherapy may be a feasible approach to address these unmet needs. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
